Chemoprevention Trial of Selenium and Prostate Cancer

Abstract

The principal purpose of this trial is to assess the potential for the essential nutrient selenium (Se) to modulate biomarkers of prostate cancer between initial diagnostic biopsy and radical prostatectomy. The scope of work is to randomize at least 110 participants to either a placebo or Se dosages of 200 mug, or 400 mug/day. Recruitment is continuing as a result of a no-cost extension. A total of 79 subjects have been randomized. Of these, 72 have completed the study, 6 dropped before completing the study, and 1 is in the process of completing the study.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Apr 01, 2003
Accession Number
ADA415790

Entities

People

  • Frederick R. Ahmann
  • M. S. Stratton

Organizations

  • University of Arizona

Tags

DTIC Thesaurus Topics

  • Biological Markers
  • Biomedical Research
  • Cells
  • Clinical Trials
  • Data Analysis
  • Drug Therapy
  • Laboratory Animals
  • Materials
  • Medical Personnel
  • North America
  • Prostate
  • Prostate Cancer
  • Recombinant Dna
  • Selenium
  • Standards
  • Tissues
  • Vitamin E

Fields of Study

  • Medicine

Readers

  • Clinical Trial Research.
  • Materials Science and Engineering.
  • Oncology

Technology Areas

  • Biotechnology